ASPA gene modulator (Passage Bio/University of Pennsylvania)

N/A

Report date: 2025/01/26 17:28:30

Base Information

Drug NameASPA gene modulator (Passage Bio/University of Pennsylvania)
Drug Alias NameAAV gene therapy for canavan disease (Passage Bio/University of Pennsylvania)
ClassificationBiologics
Mechanisms of ActionASPA gene modulators
TargetsAspartoacylase
Therapy Area/IndicationsCanavan Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPassage Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesPassage Bio IncUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsCanavan Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A